nemolizumab

04/01/2018 - "Nemolizumab had similar EASI-75 responses as placebo, but significantly improved pruritus. "
01/01/2022 - "Nemolizumab 60 mg Q4W with concomitant topical treatments in patients with AD and inadequately controlled moderate-to-severe pruritus produced a continuous improvement in pruritus, signs of AD, and QoL for up to 68 weeks, with a favourable safety profile."
04/01/2023 - "Subcutaneous administration of nemolizumab ameliorated pruritus and skin signs, and thereby produced improvement in patient QOL across multiple PRO measures, including sleep, interpersonal relationships, and the ability to conduct social or work activities. "
01/01/2022 - "Furthermore, our results demonstrate how transcriptomic changes associated with nemolizumab treatment correlate with improvement in lesions, pruritus, stabilization of extracellular matrix remodeling, and processes associated with cutaneous nerve function. "
10/01/2018 - "In 153 patients randomized to nemolizumab in part A, improvement from baseline in pruritus visual analog scale score was maintained/increased from weeks 12 to 64, with greatest improvement in the 0.5-mg/kg Q4W group (percentage change from baseline at week 64: -73.0, -89.6, -74.7, and -79.1 in the 0.1-, 0.5-, and 2.0-mg/kg Q4W and 2.0-mg/kg Q8W groups, respectively). "

07/01/2021 - "Nemolizumab is associated with a rapid improvement in atopic dermatitis signs and symptoms: subpopulation (EASI ≥ 16) analysis of randomized phase 2B study."
04/01/2021 - "Efficacy and Safety of Nemolizumab for Treatment of Adult Atopic Dermatitis: A Meta-analysis of Randomized Clinical Trials."
01/01/2020 - "Longer and larger trials are necessary to determine whether nemolizumab has a durable effect and is safe for atopic dermatitis. "
01/01/2020 - "In phase 2 studies, nemolizumab lessened the severity of atopic dermatitis. "
08/01/2019 - "This study investigated the impact of nemolizumab on work productivity and activity impairment in adults with moderate to severe atopic dermatitis inadequately controlled by topical treatments in a two-part, phase II, randomized control trial. "

10/26/2023 - "Nemolizumab monotherapy significantly reduced the signs and symptoms of prurigo nodularis. "
10/26/2023 - "Phase 3 Trial of Nemolizumab in Patients with Prurigo Nodularis."
01/01/2020 - "Larger and longer trials are needed to determine the durability and safety of nemolizumab for the treatment of prurigo nodularis. "
01/01/2020 - "Trial of Nemolizumab in Moderate-to-Severe Prurigo Nodularis."
10/26/2023 - "Nemolizumab, an interleukin-31 receptor alpha antagonist, down-regulates key pathways in the pathogenesis of prurigo nodularis. "

10/01/2023 - "The efficacy of Nemolizumab in improving cutaneous signs of inflammation and pruritus in AD and its safety profile, combined with popPK and PK/PD analyses, supported selection of the flat-dose regimen of 30 mg (with a 60 mg loading dose) given every 4 weeks subcutaneously for 16 weeks in the phase 3 ARCADIA studies sponsored by Galderma. "
07/01/2021 - "Nemolizumab resulted in very rapid, sustained improvements of inflammation, pruritus and sleep in patients with EASI ≥ 16 at baseline."
01/01/2020 - "Nemolizumab resulted in rapid and sustained improvements in cutaneous signs of inflammation and pruritus in patients with AD, with maximal efficacy observed at 30 mg. "
02/08/2023 - "Nemolizumab is a humanized monoclonal antibody that antagonizes IL-31RA, inhibiting the IL-31 cascade and therefore contributing to reducing the pruritus and inflammation and recovering the damaged skin barrier in AD patients. "
10/01/2023 - "Nemolizumab is a monoclonal antibody directed against the interleukin-31 receptor A subunit, which is involved in the pathogenesis of pruritus and inflammation in atopic dermatitis (AD). "

04/01/2022 - "Nemolizumab demonstrates great efficacy in reducing pruritus and to a lesser degree, dermatitis associated with AD. "
10/01/2018 - "Nemolizumab, an anti-IL-31 receptor A mAb, improved pruritus, dermatitis, and sleep in adults with moderate-to-severe atopic dermatitis that was inadequately controlled by topical treatments in a phase II, 12-week, randomized, double-blind, placebo-controlled study (part A; NCT01986933). "